Compositions and methods for treating CNS disorders

Patent metadata

Field	Value
Publication number	US-11718642-B2
Application number	US-201916961097-A
Country	US
Kind code	B2
Filing date	Jan 11, 2019
Priority date	Jan 12, 2018
Publication date	Aug 8, 2023
Grant date	Aug 8, 2023

Abstract

Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g. in the treatment of CNS-related disorders.

First claim

The invention claimed is:

1. A compound of Formula (II-IIwa), (II-IIwb), or (II-IIwc)

or a pharmaceutically acceptable salt thereof, wherein
m is 0, 1, 2, or 3;
p is 0, 1, or 2; and
each R 32 is independently halogen, C 1-6 alkyl, hydroxyl, or cyano.

2. The compound or pharmaceutically acceptable salt of claim 1 , wherein m is 1, and p is 1.

3. A compound selected from

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 1 or claim 3 , and a pharmaceutically acceptable excipient.

5. A method for treating a CNS-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1 or claim 3 , wherein the CNS-related disorder is a sleep disorder, a mood disorder, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, tinnitus, or status epilepticus.

6. The method of claim 5 , wherein the CNS-related disorder is a mood disorder, and wherein the mood disorder is depression.

7. The method of claim 6 , wherein the depression is postpartum depression or a major depressive disorder.

8. The method of claim 7 , wherein the major depressive disorder is a moderate major depressive disorder or a severe major depressive disorder.

9. The method of claim 5 , wherein the CNS-related disorder is a movement disorder, and wherein the movement disorder is seizure or tremor.

10. The method of claim 9 , wherein the tremor is essential tremor.

11. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (II-IIwa), (II-IIwb), or (II-IIwc) is a compound of Formula (II-IIwa):

or a pharmaceutically acceptable salt thereof.

12. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (II-IIwa), (II-IIwb), or (II-IIwc) is a compound of Formula (II-IIwb):

or a pharmaceutically acceptable salt thereof.

13. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound of Formula (II-IIwa), (II-IIwb), or (II-IIwc) is a compound of Formula (II-IIwc):

or a pharmaceutically acceptable salt thereof.

Assignees

• Sage Therapeutics Inc

Inventors

• Robichaud Albert Jean
• Salituro Francesco G
• Blanco-Pillado Maria Jesus
• La Daniel
• Harrison Boyd L

Classifications

• C07J73/003 Primary

  by oxygen as hetero atom · CPC title

• C07J73/005

  by nitrogen as hetero atom · CPC title

• C07J73/006

  by sulfur as hetero atom · CPC title

• C07J75/005

  Preparation of steroids by cyclization of non-steroid compounds · CPC title